证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-049 丽珠医药集团股份有限公司关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 丽珠医药集团股份有限公司（以下简称"公司"）于 2024 年 12 月 24 日召 开了公司 2024 年第四次临时股东大会、2024 年第二次 A 股类别股东会及 2024 年第二次 H 股类别股东会，审议通过了《关于回购公司部分 A 股股份方案的议 案》，于 2025 年 5 月 29 日召开了公司 2024 年度股东大会、2025 年第一次 A 股 类别股东会及 2025 年第一次 H 股类别股东会，审议通过了《关于继续实施回购 公司部分 A 股股份方案的议案》及《关于授予董事会回购本公司 H 股的一般授 权》。现将公司回购股份的进展情况公告如下： 一、回购 A 股股份的进展情况 二、回购 H 股股份的进展情况 根据回购本公司 H 股的一般授权，公司将通过香港联合交易所有限公司进 行场内回购，每次回购价格不高于相关回购日前 5 个交易日平均收盘价的 5%， 回购的 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-048 丽珠医药集团股份有限公司 关于获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 剂型：注射剂 申请事项：临床试验申请 注册分类：化学药品 1 类 申请人：丽珠医药集团股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 4 月 14 日受理的 YJH-012 注射液临床试验申请符合药品注册的有关要求，同 意本品开展痛风适应症临床试验。 二、药品研发及相关情况 近日，丽珠医药集团股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的《药物临床试验批准通知书》（通知书编号：2025LP01629）， 批准 YJH-012 注射液开展临床试验。现将有关详情公告如下： 一、药物临床试验批准通知书的主要内容 药物名称：YJH-012 注射液 三、药品的市场情况 根据CDE审评中心网站显示，截至目前，国内无同适应症小核酸产品上市。 四、风险提示 由于药物研发的特殊性，从临床试验到投产上市的周期长、环节多 ...

Core Viewpoint - The company announced that its subsidiary, Lizhu Group, received approval from the National Medical Products Administration for clinical trials of YJH-12 injection, a new siRNA drug for gout [1] Group 1: Company Developments - Lizhu Group, a subsidiary of the company, is collaborating with Youjia (Hangzhou) Biopharmaceutical Technology Co., Ltd. to develop the YJH-12 injection [1] - The total research and development expenses incurred for YJH-12 injection amount to approximately RMB 25.7386 million [1] - There are currently no similar small nucleic acid products approved for the same indication in the domestic market [1]

Core Viewpoint - The article highlights the ongoing issues with the timely supply of drugs and medical devices following centralized procurement in various regions of China, indicating a significant number of products have not established delivery relationships post-selection, which raises concerns about the reliability of selected suppliers [1][9]. Group 1: Issues with Drug Supply - As of May 31, 2023, 443 drug specifications have not established timely delivery relationships after centralized procurement in Guangzhou, with nearly 70% of the 221 identified underperforming products having a delivery rate of 0 [9][10]. - The Hebei Provincial Medical Procurement Center has announced that certain companies will be rated as "generally" untrustworthy due to inadequate delivery services, including Suzhou Terui Pharmaceutical and Lizu Group, which are involved in multiple national procurement batches [2][5]. Group 2: Specific Products and Companies - Lizu Group's voriconazole injection was selected in the eighth batch of national procurement at a price of 29.19 yuan per unit, a significant drop from its previous market price of 700-800 yuan, reflecting a price reduction of over 90% [2]. - Northland Pharmaceutical's iohexol injection was selected in the seventh batch of national procurement at a price of 91.3 yuan per unit, being the only contrast agent selected in that batch [3]. Group 3: Regulatory Framework and Consequences - The Hebei Provincial Medical Procurement Center has established a credit evaluation system for pharmaceutical pricing and procurement, categorizing untrustworthy behavior into four levels: "general," "medium," "serious," and "particularly serious" [7]. - Companies identified as untrustworthy may face consequences such as written warnings, risk notifications on procurement platforms, and restrictions on the procurement qualifications of related drugs and materials [7]. Group 4: Broader Supply Issues - Beyond medical institutions, there are also reported supply shortages in designated pharmacies, with 422 drugs not supplied, affecting various products and involving 289 manufacturers [8].

Core Viewpoint - The announcement from the Hebei Provincial Medical Supplies Procurement Center indicates that several companies are being rated as "generally" untrustworthy due to inadequate delivery services for selected products in the national centralized procurement process [1][2][3] Group 1: Companies Involved - Companies listed for potential untrustworthiness include Suzhou Terui Pharmaceutical, Sihuan Pharmaceutical, Lijun Group, Jiangxi Yongfeng Kande Pharmaceutical, Guangdong Saifeng Pharmaceutical, Beijing Fule Technology, and Beijing Beilu Pharmaceutical [1][2] - Lijun Group's voriconazole injection was selected in the eighth batch of national procurement at a price of 29.19 yuan per unit, down from a previous market price of 700-800 yuan, representing a price drop of over 90% [1] - Beilu Pharmaceutical's iopamidol injection was selected in the seventh batch of national procurement at a price of 91.3 yuan per unit, being the only contrast agent selected in that batch [1] Group 2: Regulatory Framework - The Hebei Provincial Medical Security Bureau established a credit evaluation system for drug pricing and procurement in late 2020, categorizing untrustworthy behavior into four levels: "general," "moderate," "serious," and "particularly serious" [3] - The "general" untrustworthiness rating applies to companies that fail to fulfill procurement or delivery contracts without valid reasons and do not notify procurement agencies in advance, provided it does not severely impact clinical treatment [3] - Once a company is rated as untrustworthy, the provincial procurement center will implement measures such as written warnings, risk notifications on procurement platforms, and restrictions on procurement qualifications [3] Group 3: Broader Industry Context - The issue of supply shortages is not limited to medical institutions; designated pharmacies in Hebei also face significant shortages, with 422 drugs reported as unavailable [4] - Other regions, including Liaoning, Hainan, and Guangzhou, have also reported issues with selected companies failing to deliver drugs on time since the implementation of centralized procurement policies [4] - As of May 31, 2023, 443 drug varieties had not established timely delivery relationships post-procurement, with nearly 70% of the identified varieties having a delivery rate of 0% [4] Group 4: Future Developments - By the end of 2024, 612 companies were rated as generally untrustworthy, 76 as moderately untrustworthy, 40 as seriously untrustworthy, and 7 as particularly seriously untrustworthy [5] - A new standard for credit evaluation will be implemented starting from the third quarter of 2025, simplifying the rating system from four levels to three: "untrustworthy," "seriously untrustworthy," and "particularly seriously untrustworthy" [6]

Group 1 - The stock price of Lijun Group (000513) closed at 36.49 yuan on June 6, 2025, up 0.25% from the previous week [1] - The company's total market capitalization is 32.991 billion yuan, ranking 14th out of 150 in the chemical pharmaceutical sector and 423rd out of 5148 in the A-share market [1] - The highest intraday price reached 37.99 yuan on June 5, 2025, while the lowest was 36.28 yuan on June 3, 2025 [1] Group 2 - Lijun Group plans to repurchase A-shares and H-shares, with 11,318,855 A-shares repurchased, accounting for 1.25% of the total share capital, and a total expenditure of approximately 406.84 million yuan [1][3] - The company has also repurchased and canceled 7,245,300 H-shares, with no new H-share repurchase planned [1][3] - The 2024 annual equity distribution plan for A-shares includes a cash dividend of 11.00 yuan per 10 shares, totaling approximately 652.27 million yuan [1][3]

Core Viewpoint - The company has announced a cash dividend distribution plan for its A-share shareholders, with a total cash dividend amounting to RMB 652,271,903.80 (including tax), translating to a cash dividend of RMB 11.00 per 10 shares for the fiscal year 2024 [1][2]. Group 1: Dividend Distribution Details - The cash dividend distribution is based on the total A-share capital of 604,293,313 shares, excluding repurchased but not canceled shares [1]. - The cash dividend per share after the distribution will be RMB 1.0793961, which will be deducted from the closing price on the ex-dividend date [2]. - The dividend distribution plan was approved at the company's annual general meeting held on May 29, 2025 [2]. Group 2: Shareholder Eligibility and Taxation - The eligible A-share shareholders for the dividend are those registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of June 12, 2025 [3]. - For Hong Kong market investors and foreign institutions, the cash dividend will be RMB 9.90 per 10 shares after tax deductions [2]. - The company will not withhold individual income tax for certain shareholders, with tax obligations calculated based on the holding period upon stock transfer [3]. Group 3: Important Dates - The record date for the dividend distribution is set for June 12, 2025, and the ex-dividend date is June 13, 2025 [3].

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-047 丽珠医药集团股份有限公司 2024 年年度权益分派（A 股）实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： ●截至本公告日，丽珠医药集团股份有限公司（以下简称"本公司"或"公 司"）A 股股本为 604,293,313 股，公司回购专用证券账户持有公司股份 11,318,855 股，根据《上市公司股份回购规则》的规定，回购专用证券账户股份 不享有利润分配和资本公积金转增股本的权利。本次权益分派实施后，按公司 A 股股本（含回购但未注销股份）折算每 10 股现金分红（含税）比例及除权除息 参考价如下： 公司本次实际现金分红总金额（含税）=实际参与分配股本×分配比例，即 592,974,458 股×1.10 元/股（含税）=652,271,903.80 元（含税）；按公司 A 股股 本（含回购但未注销股份）折算的每 10 股现金分红（含税）比例=本次实际现金 分红总金额÷A 股股本（含回购但未注销股份）×10，即 652,271,903.80（含税） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年5月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 麗珠醫藥集團股份有限公司 呈交日期: 2025年6月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 307,052,417 | RMB | | 1 RMB | | 307,052,417 | | 增加 / 減少 (-) | | | -7,245,300 | | | RMB | | -7,245,300 | | 本月底結存 | | | 299,807,117 | RMB | | 1 RMB | | 299,807,117 | 本月底法定/註冊股本總額： ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-046 根据回购本公司 H 股的一般授权，公司将通过香港联合交易所有限公司进 行场内回购，每次回购价格不高于相关回购日前 5 个交易日平均收盘价的 5%， 回购的 H 股股份将用于注销减少注册资本。 于 2025 年 5 月 14 日，已回购的公司 H 股股份共计 7,245,300 股已完成注 销。截至目前，本次回购 H 股的一般授权下，尚未进行 H 股回购。 丽珠医药集团股份有限公司关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 丽珠医药集团股份有限公司（以下简称"公司"）于 2024 年 12 月 24 日召 开了公司 2024 年第四次临时股东大会、2024 年第二次 A 股类别股东会及 2024 年第二次 H 股类别股东会，审议通过了《关于回购公司部分 A 股股份方案的议 案》，于 2025 年 5 月 29 日召开了公司 2024 年度股东大会、2025 年第一次 A 股 类别股东会及 2025 年第一次 H 股类别股东会，审议通过了《关 ...